Australia's most trusted
source of pharma news
Thursday, 04 September 2025
Posted 1 September 2025 AM
BMS’ broad access proposal for Opdivo and Yervoy plus two potential PBS debutants are among six submissions on the PBAC’s September intracycle meeting.
The PBAC deferred BMS’ multi-indication listing proposal of Opdivo and Yervoy in unresectable advanced and metastatic cancer at the recent July meeting – the same meeting that it knocked back MSD's similar proposal for Keytruda.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.